表紙:世界の糖尿病および関連疾患に対する幹細胞治療市場:2021~2028年
市場調査レポート
商品コード
1022290

世界の糖尿病および関連疾患に対する幹細胞治療市場:2021~2028年

Global Stem Cell Therapy for Diabetes and Related Conditions Market - 2021-2028

出版日: | 発行: DataM Intelligence | ページ情報: 英文 180 Pages | 納期: 約2営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=135.61円
世界の糖尿病および関連疾患に対する幹細胞治療市場:2021~2028年
出版日: 2021年08月06日
発行: DataM Intelligence
ページ情報: 英文 180 Pages
納期: 約2営業日
● ご注意事項
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 目次
概要

世界の糖尿病および関連疾患に対する幹細胞治療の市場規模は今後拡大すると予測されています。

当レポートでは、世界の糖尿病および関連疾患に対する幹細胞治療市場について調査し、市場の概要とともに、タイプ別、用途別、地域別の動向、および市場に参入する企業のプロファイルなどを提供しています。

目次

第1章 世界の糖尿病および関連疾患に対する幹細胞治療市場の調査手法と範囲

  • 調査手法
  • 調査の目的と調査範囲

第2章 世界の糖尿病および関連疾患に対する幹細胞治療市場-市場の定義と概要

第3章 世界の糖尿病および関連疾患に対する幹細胞治療市場-エグゼクティブサマリー

  • タイプ別の市場内訳
  • 用途別の市場内訳
  • 地域別の市場内訳

第4章 世界の糖尿病および関連疾患に対する幹細胞治療市場-市場力学

  • 市場に影響を与える要因
    • 促進要因
    • 抑制要因
    • 市場機会
    • 影響分析

第5章 世界の糖尿病および関連疾患に対する幹細胞治療市場-業界分析

  • ポーターのファイブフォース分析
  • PEST分析
  • サプライチェーン分析
  • 価格分析
  • 規制分析
  • 償還分析
  • アンメットニーズ

第6章 世界の糖尿病および関連疾患に対する幹細胞治療市場-COVID-19分析

  • 市場でのCovid-19の分析
    • COVID-19前の市場シナリオ
    • COVID-19現在の市場シナリオ
    • COVID-19後または将来のシナリオ
  • Covid-19における価格のダイナミクス
  • 需要と供給のスペクトル
  • パンデミック時の市場に関連する政府のイニシアチブ
  • メーカーの戦略的イニシアチブ
  • 結論

第7章 世界の糖尿病および関連疾患に対する幹細胞治療市場-タイプ別

  • イントロダクション
    • 市場規模分析、および前年比成長分析(%)、タイプ別
    • 市場魅力指数
  • 併用療法
    • イントロダクション
    • 市場規模分析、百万米ドル、2018~2028年、および前年比成長分析(%)、2020~2028年
  • 単剤療法

第8章 世界の糖尿病および関連疾患に対する幹細胞治療市場-用途別

  • イントロダクション
    • 市場規模分析、および前年比成長分析(%)、用途別
    • 市場魅力指数
  • 1型糖尿病*
    • イントロダクション
    • 市場規模分析、百万米ドル、2018~2028年、および前年比成長分析(%)、2020~2028年
  • 2型糖尿病
  • 糖尿病性足潰瘍
  • 糖尿病性腎症
  • 糖尿病性ニューロパチー

第9章 世界の糖尿病および関連疾患に対する幹細胞治療市場-地域別

  • イントロダクション
    • 市場規模分析、百万米ドル、2018~2028年、および前年比成長分析(%)、2020~2028年、地域別
    • 市場魅力指数
  • 北米
    • イントロダクション
    • 主要な地域固有のダイナミクス
    • 市場規模分析、および前年比成長分析(%)、タイプ別
    • 市場規模分析、および前年比成長分析(%)、用途別
    • 市場規模分析、および前年比成長分析(%)、国別
  • 欧州
    • イントロダクション
    • 主要な地域固有のダイナミクス
    • 市場規模分析、および前年比成長分析(%)、タイプ別
    • 市場規模分析、および前年比成長分析(%)、用途別
    • 市場規模分析、および前年比成長分析(%)、国別
  • 南米
    • イントロダクション
    • 主要な地域固有のダイナミクス
    • 市場規模分析、および前年比成長分析(%)、タイプ別
    • 市場規模分析、および前年比成長分析(%)、用途別
    • 市場規模分析、および前年比成長分析(%)、国別
  • アジア太平洋
    • イントロダクション
    • 主要な地域固有のダイナミクス
    • 市場規模分析、および前年比成長分析(%)、タイプ別
    • 市場規模分析、および前年比成長分析(%)、用途別
    • 市場規模分析、および前年比成長分析(%)、国別
  • 中東とアフリカ
    • イントロダクション
    • 主要な地域固有のダイナミクス
    • 市場規模分析、および前年比成長分析(%)、タイプ別
    • 市場規模分析、および前年比成長分析(%)、用途別

第10章 糖尿病および関連する状態の市場のための世界の幹細胞治療-競合情勢

  • 主な発展と戦略
  • 企業シェア分析
  • 製品のベンチマーク
  • 注目すべき主要企業
  • 破壊的技術を持つ企業
  • スタートアップ企業

第11章 世界の糖尿病および関連疾患に対する幹細胞治療市場-企業プロファイル概要

  • Caladrius Biosciences
    • 企業概要
    • タイプポートフォリオと概要
    • 主なハイライト
    • 財務概要
  • Athersys
  • Mesoblast
  • Sanofi
  • Novo Nordisk
  • Cellonis Biotechnology Co. Ltd(China)
  • Shanghai Biotechnology Co., Ltd(China)

非網羅的リスト

第12章 世界の糖尿病および関連疾患に対する幹細胞治療市場-DataM

  • 付録
  • 当社・サービスについて
  • お問い合わせ
目次
Product Code: DMPH3822

Stem Cell Therapy for Diabetes and Related Conditions Market Overview

The global stem cell therapy for diabetes and related conditions market size was valued US$ XX billion in 2019 and is estimated to reach US$ XX billion by 2028, growing at a CAGR of XX % during the forecast period (2021-2028).

Stem Cell Therapy for Diabetes and Related Conditions Market Dynamics

The stem cell therapy for diabetes and related conditions market growth is driven by the increasing prevalence of diabetes and the growing inclination of the major diabetic populations toward use of advanced therapies to manage their diabetes has led to a surge in demand for stem cell therapy for diabetes.

Increasing prevalence of diabetes, is expected to drive the growth in the forecast period

The rising prevalence of diabetes is expected to fuel the growth of the disposable insulin pump market over the forecast period. For example, as per the International Diabetes Federation, around 463 million people in the age group of 20 to 79 years were reported to be suffering from diabetes in 2019, and it has been estimated that by 2045, the number will increase to 700 million. Furthermore, according to the same source, in 2019, diabetes caused around 4.2 million deaths. People with type 1 diabetes are increasing in most countries, and around 374 million people are expected to suffer from type 2 diabetes. Furthermore, over 1.1 children and adolescents currently have type 1 diabetes. In 2019, around 760 billion dollars were spent by the U.S. government for diabetes as healthcare expenditure.

Major side-effects of stem cell transplants are likely to hamper the market.

Stem cell transplants cause several immediate side effects such as fatigue, vomiting, low platelets and red blood cells, and diarrhea. It may also cause several long-term effects such as infertility, eye disorders, early menopause, lung and bone damage, and risk of developing other cancer types. Sometimes after allogeneic transplants, Graft Versus Host Disease (GVHD) occurs if the stem cells from the donor aren't a close enough match to the patient's own. These risk factors may hamper the growth of the global stem cell therapy for diabetes and related conditions market size.

COVID-19 Impact Analysis

The COVID-19 pandemic is expected to impact the stem cell therapy for diabetes and related conditions market negatively. Following the COVID-19 outbreak in December 2019, the disease has spread to over 100 countries globally, and the World Health Organization has declared it a public health emergency. According to the World Health Organization's report, the coronavirus (COVID-19) manifestation has resulted in more than 52.7 million infected individuals worldwide as of November 13, 2020. COVID-19 has affected every market globally and has also impacted the global stem cell therapy for diabetes and related conditions market in the following ways; by directly affecting production and demand, creating disruptions in distribution channels, and its financial impact on firms and financial markets.

Stem Cell Therapy for Diabetes and Related Conditions Market Segment Analysis

The combination therapy segment is expected to hold largest share in this market segment

A combination of stem cell and drug therapy could reverse diabetes. The combination of stem cell transplants and antidiabetic drugs substantially improves the ability to process glucose. The metformin (Glucophage) reduces the rate at which the liver manufactures glucose, and sitagliptin (Januvia) boosts insulin production and regulates blood sugar.

The type 1 diabetes mellitus segment is expected to hold largest share in this market segment

Diabetes is a chronic, life-threatening disease with an unknown cure. It has been emerged as a global epidemic and affected millions globally. Furthermore, Type 1 diabetes is caused due to an immune system malfunction. Hence, Type 1 diabetes can be characterized most by insulin-requiring.

At present, China has the highest number of diabetes patients in the world. In addition, the prevalence of diabetes in China has risen substantially over the past decade. For instance, according to WHO, in 2020, China had about 126.80 million diabetic patients, and this number is expected to reach 138.42 million by the end of 2026. China's urbanization and growing living standards, leading to reduced physical activity and unhealthy diets, are the significant factors behind the high rate of diabetes. In 2020, China accounted for 9.8% of Type 1 diabetes patients of the total diabetes population.

Stem Cell Therapy for Diabetes and Related Conditions Market Geographical Analysis

North America region holds the largest market share of global stem cell therapy for diabetes and related conditions market

The North American region is expected to hold a dominant position in the global stem cell therapy for diabetes and related conditions market over the forecast period, owing to the increasing prevalence of diabetes in the U.S. population. For instance, according to American Diabetes Association, 2018, in 2018, around 34.2 million U.S. population were reported to have diabetes. Out of which, 26.8 million were diagnosed, and 7.3 million were undiagnosed. Moreover, 14.3 million people constitute the older population (above the age of 65 years) are suffering from diabetes. Moreover, diabetes is the seventh leading cause of death in the U.S. population, with around 76,000 deaths annually in the U.S. every year.

Additionally, reimbursements policies provided by the government to the patients are expected to fuel the global stem cell therapy for diabetes and related conditions market growth over the forecast period. For instance, according to the Centers for Disease Control and Prevalence (CDC), 2018, in the U.S., Diabetes Self-Management Education and Support (DSMES) provides education for the patients for increasing their knowledge and skills for the management of diabetes. DSMES are funded by Medicaid, which aids in reducing the health care cost of the patients.

Stem Cell Therapy for Diabetes and Related Conditions Market Competitive Landscape

The global stem cell therapy for diabetes and related conditions market is highly competitive with presence of global companies. Some of the key players which are contributing to the growth of the market include Athersys, Mesoblast, Caladrius Biosciences, Sanofi, Novo Nordisk, Cellonis Biotechnology Co. Ltd (China), Shanghai Biotechnology Co., Ltd (China). The major players are adopting several growth strategies such as product launches, acquisitions, and collaborations, which are contributing to the growth of the market globally. For instance, NSI-566 is the stem cell therapy candidate under development by one of the key companies Neuralstem. The molecule is being developed for the treatment of individuals with diabetic neuropathy and is currently in the pre-clinical development stage. The mechanism of action of this stem cell therapy includes cell replacement that eventually leads to neurogenesis stimulation.

Stem Cell Therapy for Diabetes and Related Conditions Market Key Companies to Watch

Caladrius Biosciences

Overview: Caladrius is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of cell therapies designed to reverse disease and/or promote the regeneration of damaged tissue. The Company is developing first-in-class therapeutics based on the characteristics of naturally occurring CD34+ cells and their ability to stimulate the growth of new microvasculature. The Company's platform technology leverages these cells to enable the body's natural repair mechanisms using formulations unique to each medical indication.

Key Developments: Caladrius developing CLBS201 to treat diabetic nephropathy is under Phase 2 trials.

Why Purchase the Report?

  • Visualize the composition of the stem cell therapy for diabetes and related conditions market segmentation by type, application and region highlighting the key commercial assets and players.
  • Identify commercial opportunities in stem cell therapy for diabetes and related conditions market by analysing trends and co-development deals.
  • Excel data sheet with thousands of data points of stem cell therapy for diabetes and related conditions market - level 4/5 segmentation.
  • PDF report with the most relevant analysis cogently put together after exhaustive qualitative interviews and in-depth market study.
  • Product mapping in excel for the key product of all major market players

The global stem cell therapy for diabetes and related conditions market report would provide an access to an approx. 38 market data table, 38 figures and 200 pages.

Target Audience

  • Service Providers/ Buyers
  • Industry Investors/Investment Bankers
  • Education & Research Institutes
  • Research Professionals
  • Emerging Companies
  • Manufacturers

Market Segmentation

Global Stem Cell Therapy for Diabetes and Related Conditions Market - By Type

  • Monotherapy
  • Combination Therapy

Global Stem Cell Therapy for Diabetes and Related Conditions Market - By Application

  • Type 1 Diabetes Mellitus
  • Type 2 Diabetes Mellitus
  • Diabetic Foot Ulcer
  • Diabetic Nephropathy
  • Diabetic Neuropathy

Global Stem Cell Therapy for Diabetes and Related Conditions Market - By Region

  • North America
  • Europe
  • Asia-Pacific
  • Middle East & Africa
  • South America

Table of Contents

1. Global Stem Cell Therapy for Diabetes and Related Conditions Market Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Global Stem Cell Therapy for Diabetes and Related Conditions Market - Market Definition and Overview

3. Global Stem Cell Therapy for Diabetes and Related Conditions Market - Executive Summary

  • 3.1. Market Snippet by Type
  • 3.2. Market Snippet by Application
  • 3.3. Market Snippet by Region

4. Global Stem Cell Therapy for Diabetes and Related Conditions Market - Market Dynamics

  • 4.1. Market Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Increasing prevalence of diabetes
    • 4.1.2. Restraints:
      • 4.1.2.1. Major side-effects of stem cell transplants
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Global Stem Cell Therapy for Diabetes and Related Conditions Market - Industry Analysis

  • 5.1. Porter's Five Forces Analysis
  • 5.2. PEST Analysis
  • 5.3. Supply Chain Analysis
  • 5.4. Pricing Analysis
  • 5.5. Regulatory Analysis
  • 5.6. Reimbursement Analysis
  • 5.7. Unmet Needs

6. Global Stem Cell Therapy for Diabetes and Related Conditions Market - COVID-19 Analysis

  • 6.1. Analysis of Covid-19 on the Market
    • 6.1.1. Before COVID-19 Market Scenario
    • 6.1.2. Present COVID-19 Market Scenario
    • 6.1.3. After COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid Covid-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturers Strategic Initiatives
  • 6.6. Conclusion

7. Global Stem Cell Therapy for Diabetes and Related Conditions Market - By Type

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 7.1.2. Market Attractiveness Index, By Type
  • 7.2. Combination Therapy*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis, US$ Million, 2018-2028 and Y-o-Y Growth Analysis (%), 2020-2028
  • 7.3. Monotherapy

8. Global Stem Cell Therapy for Diabetes and Related Conditions Market - By Application

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application Segment
    • 8.1.2. Market Attractiveness Index, By Application Segment
  • 8.2. Type 1 Diabetes Mellitus*
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis, US$ Million, 2018-2028 and Y-o-Y Growth Analysis (%), 2020-2028
  • 8.3. Type 2 Diabetes Mellitus
  • 8.4. Diabetic Foot Ulcer
  • 8.5. Diabetic Nephropathy
  • 8.6. Diabetic Neuropathy

9. Global Stem Cell Therapy for Diabetes and Related Conditions Market - By Region

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis, US$ Million, 2018-2028 and Y-o-Y Growth Analysis (%), 2020-2028, By Region
    • 9.1.2. Market Attractiveness Index, By Region
  • 9.2. North America
    • 9.2.1. Introduction
    • 9.2.2. Key Region-Specific Dynamics
    • 9.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 9.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 9.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 9.2.5.1. U.S.
      • 9.2.5.2. Canada
      • 9.2.5.3. Mexico
  • 9.3. Europe
    • 9.3.1. Introduction
    • 9.3.2. Key Region-Specific Dynamics
    • 9.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 9.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 9.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 9.3.5.1. Germany
      • 9.3.5.2. U.K.
      • 9.3.5.3. France
      • 9.3.5.4. Italy
      • 9.3.5.5. Spain
      • 9.3.5.6. Rest of Europe
  • 9.4. South America
    • 9.4.1. Introduction
    • 9.4.2. Key Region-Specific Dynamics
    • 9.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 9.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 9.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 9.4.5.1. Brazil
      • 9.4.5.2. Argentina
      • 9.4.5.3. Rest of South America
  • 9.5. Asia Pacific
    • 9.5.1. Introduction
    • 9.5.2. Key Region-Specific Dynamics
    • 9.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 9.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 9.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 9.5.5.1. China
      • 9.5.5.2. India
      • 9.5.5.3. Japan
      • 9.5.5.4. Australia
      • 9.5.5.5. Rest of Asia Pacific
  • 9.6. Middle East and Africa
    • 9.6.1. Introduction
    • 9.6.2. Key Region-Specific Dynamics
    • 9.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 9.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application

10. Global Stem Cell Therapy for Diabetes and Related Conditions Market - Competitive Landscape

  • 10.1. Key Developments and Strategies
  • 10.2. Company Share Analysis
  • 10.3. Product Benchmarking
  • 10.4. Key Companies to Watch
  • 10.5. Company with disruptive technology
  • 10.6. Start Up Companies

11. Global Stem Cell Therapy for Diabetes and Related Conditions Market- Company Profiles

  • 11.1. Caladrius Biosciences*
    • 11.1.1. Company Overview
    • 11.1.2. Product Portfolio and Description
    • 11.1.3. Key Highlights
    • 11.1.4. Financial Overview
  • 11.2. Athersys
  • 11.3. Mesoblast
  • 11.4. Sanofi
  • 11.5. Novo Nordisk
  • 11.6. Cellonis Biotechnology Co. Ltd (China)
  • 11.7. Shanghai Biotechnology Co., Ltd (China)

LIST NOT EXHAUSTIVE

12. Global Stem Cell Therapy for Diabetes and Related Conditions Market - DataM

  • 12.1. Appendix
  • 12.2. About Us and Services
  • 12.3. Contact Us